Sophiris Bio Inc. (SPHS)

OTCMKTS: SPHS · Delayed Price · USD
0.00 0.00 (0.00%)
Jan 24, 2022 10:02 PM EST - Market closed

Company Description

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases.

The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.

It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate.

The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.

Sophiris Bio Inc.
Sophiris Bio Logo
CountryUnited States
Founded2002
IndustryBiotechnology
SectorHealth Care
Employees6

Contact Details

Address:
1258 Prospect Street
La Jolla, CA 92037
United States
Phone858-777-1760

Stock Details

Ticker SymbolSPHS
ExchangeOTCMKTS
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001563855

Key Executives

NamePosition
Randall E. WoodsPresident, Chief Executive Officer and Director
Dr. Samuel R. Denmeade M.D.Chief Scientific Officer and Member of the Scientific Advisory Board
Dr. James Joseph BeesleySenior Director of Investor Relations
Iain R. Mant Esq.Corporate Secretary

Latest SEC Filings

DateTypeTitle
Apr 29, 202025-NSENotification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
Apr 28, 20208-KCurrent report
Apr 3, 20208-KCurrent report
Mar 31, 20208-KCurrent report
Mar 11, 20208-KCurrent report
Feb 14, 2020SC 13G/AStatement of acquisition of beneficial ownership by individuals
Jan 24, 20208-KCurrent report
Dec 23, 20194Statement of changes in beneficial ownership of securities
Dec 23, 20194Statement of changes in beneficial ownership of securities
Dec 23, 20194Statement of changes in beneficial ownership of securities
View All SEC Filings